Company: SRPT
Filing Date: 2025-12-11
Form Type: 8-K
Source: 0001193125-25-315032
Chunk: 1

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-12-11
Form: 8-K
Item: Item 3.02
Chunk 1
---
 form of Note, which are filed as Exhibits 4.1 and 4.2 to the Company’s Current Report on Form8-Kfiled on August 29, 2025 and are incorporated herein by reference.

The Exchange is expected to close on or about December 18, 2025, subject to customary closing conditions. The issuance of the New Convertible Notes will occur pursuant to the New Convertible Notes Indenture and the first supplemental indenture thereto, to be dated on or around December 18, 2025, between the Company and U. S. Bank Trust Company, National Association, as trustee.

The issuance of the New Convertible Notes under the Exchange Agreements is being made in reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended (the “ Securities Act”), provided by Section 4(a)(2) of the Securities Act. The Company relied on this exemption from registration based, in part, on representations made by the holders of the Existing Convertible Notes party to the Exchange Agreements. The New Convertible Notes will be issued only to investors that qualified as institutional “accredited investors” (as such term is defined in Rule 501 of the Securities Act) and/or “qualified institutional buyers” (as such term is defined in Rule 144A of the Securities Act).

The New Convertible Notes and the shares of the Company’s common stock, $0.0001 par value per share, issuable upon conversion thereof, if any, have not been registered under the Securities Act or the securities laws of any state or other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and such other jurisdictions.